Intellikine Signs $488 Million Deal with Infinity Pharma
Intellikine Inc. has sold global development and commercialization rights to its portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase Infinity Pharmaceuticals Inc. (Nasdaq: INFI). The deal could be worth upwards of $488.5 million, including a $13.5 million up-front payment. Intellikine has raised over $63 million in VC funding from Abingworth, CMEA Capital, Novartis Bioventures, U.S. Venture Partners, Biogen Idec, FinTech Global Capital and Sofinnova Ventures.
9 July 2010•5 mins read
